Resonance Health Ltd
AASX:RHT0.08
AUD
+0.01
(+6.49%)
ISIN
AU000000RHT2
Return %
Stock
S&P 500
1Y
67.35
14.20
3Y
41.38
81.12
5Y
-28.70
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Andrew Duncan Harrison
- Full Time Employees
- 65
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 141 Burswood Road Burswood WA Australia 6100
- IPO Date
- Oct 23, 1987
- Website
- resonancehealth.com
- Similar Companies
- Business
- Resonance Health Limited, an Australia-based healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) and related services for non-invasive MRI analysis of liver and heart iron concentration, liver fat assessment, and clinical trial support; its core products include FerriScan, a non-invasive MRI-based solution for quantifying liver iron concentration; FerriSmart, an AI-powered tool for automated real-time assessment of liver iron concentration; HepaFatScan and HepaFatSmart, MRI-based and AI-driven solutions for liver fat measurement; LiverSmart, a multi-parametric device combining FerriSmart and HepaFatSmart; CardiacT2, a service for assessing heart iron loading alongside FerriScan; and high-quality phantoms for MRI machine calibration and quality assurance. The company operates through SaMD, Resonance Clinical, and TrialsWest segments, serving clinicians managing diseases such as thalassemia, hemochromatosis, and hepatic steatosis, as well as pharmaceutical and biotech firms for clinical trials; it conducts business in Australia, Asia Pacific, North America, Europe, the Middle East, and Africa. Founded in 1987 and headquartered in Burswood, Australia, Resonance Health recently completed the acquisition of clinical research organization TrialsWest in June 2024 for A$8 million to expand its clinical trial capabilities, including site management, imaging analysis, and project support; it secured a major contract in November 2024 with Sun Pharmaceutical Industries to act as local Australian sponsor for a global clinical trial, generating an estimated A$13.8 million in revenue over 24 months through TrialsWest; and continues to pursue additional trial sites and complementary acquisitions to strengthen its position in the global pharma and clinical research markets.